Dinucleoside polyphosphates have attracted increasing interest with respect to their physiological role. Dinucleoside polyphosphates were identified in prokaryotic (1) , eukaryotic, and mammalian cells (2) .
Diadenosine tri-and tetraphosphate (Ap 3 A and Ap 4 A) 1 were the first dinucleoside polyphosphates to be identified in human platelets (3, 4) . Ap 3 A and Ap 4 A were shown to act as vasodilators (5, 6) . Diadenosine penta-and hexaphosphate (Ap 5 A, Ap 6 A) were identified and characterized as potent vasoconstrictors (7) . Recently, further dinucleoside polyphosphates containing adenosine and guanosine (Ap n G; n ϭ 3-6) or containing two guanosines (Gp n G; n ϭ 3-6) were discovered in human platelets (8) . Ap n G (n ϭ 5 or 6) are vasoactive also, whereas Gp n G have no vasoconstrictive effect on the isolated perfused rat kidney. Both Ap n G and Gp n G are growth stimulators in vascular smooth muscle cells (8) .
Recent studies suggested the existence of a further diadenosine polyphosphate (8) . In this study, anion exchange chromatography revealed an unidentified UV absorbance at a retention time of 56 min.
In the present study, a diadenosine polyphosphate containing seven phosphate groups was isolated by testing chromatographic fractions of human platelet extracts for vasoconstrictive effects on the isolated perfused rat kidney. In the following, the identification of diadenosine heptaphosphate (Ap 7 A) of human platelets and the characterization of the vasoactive effect of this substance is described.
MATERIALS AND METHODS
Chemicals-HPLC water (gradient grade) and acetonitrile were purchased from Merck (Germany), and all other substances were from Sigma (Germany).
Purification of Dinucleoside Polyphosphates from Human PlateletsFirst, human platelets were washed with an isotonic solution of NaCl and centrifuged (4000 rpm, 4°C, 10 min) twice (step 1). The supernatant was aspirated, and the pellets were frozen to Ϫ30°C. The platelet pellets were rethawed in bidistilled water (10 ml). The resulting suspension was deproteinated with 0.6 mol/liter (final concentration) perchloric acid and centrifuged (4000 rpm, 4°C, 5 min) (step 2). After adjusting the pH to 7.0 with 5 mol/liter KOH, the precipitated proteins and KClO 4 were removed by centrifugation (4000 rpm, 4°C, 5 min). 1 mol/liter triethylammonium acetate (TEAA) in water was added to the supernatant to a final concentration of 40 mmol/liter. The mixture was loaded to a preparative reversed phase column (step 3; Lichroprep RP-18 B, Merck; equilibration and sample buffer: 40 mmol/liter TEAA in water; flow rate: 5 ml/min). Nucleotides were eluted by 20% acetonitrile in water.
The lyophilized eluate of the reversed phase chromatography dissolved in 1 mol/liter ammonium acetate (pH 9.5) was loaded to a phenyl boronic acid resin (step 4). The resin was prepared according to Barnes et al. (9) . The absorbed substances were eluted with 1 mmol/liter HCl (flow rate: 1 ml/min). The eluate from the phenyl boronic acid resin with 1 mol/liter TEAA to a final concentration of 40 mmol/liter added was desalted (step 5) by a reversed phase chromatography (Lichroprep RP-18 B, Merck; equilibration and sample buffer: 40 mmol/liter TEAA in water; flow rate: 5 ml/min). The lyophilized eluate was chromatographed (step 6) by anion exchange chromatography (TSK DEAE 5 PW 150 ϫ 20 mm; Tosohaas (Japan); eluent A: 20 mmol/liter K 2 HPO 4 , pH 8; eluent B: 20 mmol/liter K 2 HPO 4 , pH 8, and 1 mol/liter NaCl in water; gradient: 0 -10 min 0 -5% B, 10 -105 min 5-35% B, 105-110 min 35-100% B; flow rate: 2.0 ml/min). Fractions were collected according to UV absorbance at 254 nm (peak fractionation). Each fraction of the anion exchange chromatography with a significant UV absorbance at 254 nm was further chromatographed (step 7) on a reversed phase column (Superspher RP-18 end-capped, 250 ϫ 4 mm, Merck; eluent A: 40 mmol/liter TEAA in water; eluent B: acetonitrile; gradient: 0 -4 min 0 -4% B, 4 -64 min 4 -11% B, 64 -70 min 11-70% B; flow rate: 0.5 ml/min). Fractions with a significant UV absorption were rechromatographed using the conditions described (step 8).
Matrix-assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS)-The lyophilized fractions from the reversed phase chromatography were examined by MALDI-MS and postsource decay (PSD)-MALDI-MS. A reflectron type time-of-flight mass spectrometer (Reflex III, Bruker, Germany) was used according to Hillenkamp and Karas (10) . The sample was mounted on an x, y, z movable stage allowing irradiation of selected sample areas. In this study, a nitrogen laser (VSL-337 ND, Laser Science) with an emission wavelength of 337 nm and 3-ns pulse duration was used. The laser beam was focused to a typical diameter of 50 m at an angle of 45°to the surface of a target. Microscopic sample observation was possible. 10 -20 single spectra were accumulated for a better signal-to-noise ratio. In MALDI-MS, large fractions of the desorbed analyte ions undergo PSD during flight in the field free drift path. Using a reflectron type time-of-flight set-up, sequence information from PSD fragment ions of precursors produced by MALDI were obtained (11) . Sample preparation for MALDI and PSD-MALDI experiments was identical. The concentrations of the analyzed substances were 1-10 mol/liter in double distilled water. 1 l of the analyte solution was mixed with 1 l of matrix solution (50 mg/ml 3-hydroxypicolinic acid in water). To this mixture, cation exchange beads (AG 50 W-X12, 200 -400-mesh, Bio-Rad) equilibrated with NH 4 ϩ as counter ion were added to remove Na ϩ and K ϩ ions. The mixture was gently dried on an inert metal surface before introduction into the mass spectrometer. The mass accuracy was approximately 0.01%.
UV Spectrometry-The substances purified to homogeneity by reversed phase chromatography were dissolved in 100 l of water (pH 6.5) and were analyzed by a UV spectrometer (UV-visible spectrophotometer model DU-600, Beckman). The UV absorption was scanned from 400 to 190 nm with a scan speed of 200 nm/min.
Synthesis of Diadenosine Heptaphosphate-Ap 7 A was synthesized in a modification of the method of Ng and Orgel (12) Measurements of Perfusion Pressure in the Isolated Perfused Rat Kidney-The effect of aliquots of the desalted and rechromatographed fractions of the anion exchange chromatography as well as authentic dinucleoside polyphosphates on vascular tone was evaluated in an isolated rat kidney perfused with a constant flow of 8 -9 ml/min while perfusion pressure was continuously monitored. Details of the preparation are given elsewhere (14) . The kidney was excised and immediately mounted into the perfusion system. The perfusion procedure generally followed the description given by van der Giet et al. (14) . Briefly, the isolated rat kidney was perfused by a peristaltic pump in a single pass system with a solution containing 115 mmol/liter NaCl, 4.6 mmol/ liter KCl, 1 mmol/liter CaCl 2 , 1.2 mmol/liter MgSO 4 , 1.2 mmol/liter NaH 2 PO 4 , 22 mmol/liter NaHCO 3 , 49 mmol/liter glucose, and 35 g of gelatine/liter (Hemaccel; Behringwerke, Marburg, Germany) and equilibrated with 95% O 2 , 5% CO 2 . The perfusion medium and the kidney were kept constant at 37°C. Perfusion flow was constant at 8 -9 ml/ min. Perfusion pressure was continuously monitored by a transducer (Gould P23) connected to a bridge amplifier (Hugo Sachs, Freiburg, Germany). Vasoconstrictor responses of the isolated perfused rat kidney to Ap 6 A, Ap 7 A, and ␣,␤-methylene ATP were assessed at basal tone after an equilibration period of 30 min. For each substance, doseresponse curves were constructed, with 5 min allowed to elapse between consecutive doses. The nonspecific P 2 purinoceptor antagonist suramin (100 mol/liter) and the P 2x purinoceptor antagonist pyridoxal phosphate 6-azophenyl-2Ј,4Ј-disulfonic acid (PPADS, 30 mol/liter) were added to the perfusate 30 min before challenge with mono-or dinucleotides. Furthermore, P 2x receptors were specifically occupied by continuous perfusion of the kidney with 10 Ϫ5 mol/liter ␣,␤-methylene ATP. This agent, which is a specific P 2x receptor agonist, is known to occupy P 2x receptor for any further activation.
Platelet Activation by Thrombin and Purification of Ap 7 A from the Supernatant-Three platelet concentrates were suspended in 300 ml of a 0.9% NaCl solution and divided into two parts. One of the parts was incubated with thrombin (0.05 units/ml) for 1 min. After this, the platelets were removed by centrifugation (4000 rpm, 4°C, 10 min). The supernatant was deproteinated with 0.6 mol/liter (final concentration) perchloric acid and centrifuged (4000 rpm, 4°C, 5 min). After adjusting pH to 7.0 with 5 mol/liter KOH, the precipitated proteins and KClO 4 were removed by centrifugation (4000 rpm, 4°C, 5 min). The supernatants of both parts of the platelets concentrates were chromatographed according to steps 3-6. The dimension and gradient of the anion exchange chromatography were modified. Conditions were as follows: column: Mono Q PC 3. Aggregometry-Venous blood was obtained from healthy volunteers who had not used antiplatelet aggregation drugs for at least 2 weeks and was collected into heparinized sample tubes (Sarstedt, Germany). Platelet-rich plasma was separated from the blood sample by centrifugation at 1000 rpm for 10 min at room temperature. Platelets in the supernatant were counted on a Coulter MD II hematology analyzer (Coulter, Germany) and adjusted with platelet-poor plasma to 250,000 platelets/l. Platelet-poor plasma was prepared from the pellet obtained in the first centrifugation step, after a further centrifugation at 4000 rpm for 10 min (room temperature).
Platelet aggregation studies were performed using the turbidimetric method according to Born (15) in a four-channel aggregometer (Labor, Germany). The instrument was adjusted with platelet-poor plasma to 100% and platelet-rich plasma to 0% of relative light transmission. Samples and reagents were prewarmed to 37°C. Aggregatory effects of Ap 7 A (final concentrations from 0.15 to 10 mol/liter) were investigated using 10 mol/liter ADP and 0.9% NaCl (DiaMed, Switzerland) as controls. Immediately after the addition of Ap 7 A, ADP, or NaCl to platelet-rich plasma, relative light transmission was recorded.
For inhibition experiments, platelet-rich plasma was preincubated for 2 min with different amounts of Ap 5 A, Ap 6 A, and Ap 7 A (up to 10 mol/liter). After the addition of ADP (final concentration 1 mol/liter), relative light transmission was recorded. Means Ϯ S.E. of maximum aggregation (maximal relative light transmission) were calculated of 4 -7 independent experiments.
RESULTS
Human platelets deproteinated with perchloric acid were concentrated by ion pair reversed phase chromatography. The affinity chromatography of the eluate by phenyl-boronic acid resin offers the possibility of the separation of mononucleoside and dinucleoside polyphosphates (8, 9) . The desalted and lyophilized eluate was fractionated by anion exchange chromatography. The anion exchange chromatogram is given in Fig.  1A .
The molecular mass of underlying substances of each peak was determined by MALDI-MS. All except the peak labeled by an arrow in Fig. 1A belong to known dinucleoside polyphosphates like Ap 3 A (3), Ap 4 A (4), Ap 5 A, and Ap 6 A (7) as well as Ap n G and Gp n G (with n ϭ 3-6) (8). Only the labeled peak (Fig.  1A) had not been identified earlier and had a vasoconstrictive effect in the isolated perfused rat kidney. Therefore, in the following only the identification of the peak at 86.8 min (Fig.  1A) is described. Fig. 1B shows a typical chromatogram of a reversed phase chromatography from the peak labeled in Fig. 1A . The substance eluting at a retention time of 56 min had a vasoconstrictive effect on the isolated perfused rat kidney (data not shown). Therefore, this fraction was rechromatographed by reversed phase chromatography using the same conditions as before. In the last chromatographic step, a single UV peak was obtained (Fig. 1C) .
The UV spectrum of the isolated fraction was essentially identical to that of adenosine, confirming that a nucleotide containing adenosine was present in the isolated fraction (data not shown).
In Fig. 2A , the PSD-MALDI-MS spectrum of the fraction labeled by an arrow in Fig. 1C is shown. The molecular mass of the isolated substance was determined as 1076. 4 
(1077.4 ϭ [M ϩ H]
ϩ ) Da by this PSD-MALDI-MS spectrum ( Fig. 2A) . This molecular mass as well as the fragments corresponds to that of authentic Ap 7 A (Fig. 2B) . Retention time of the isolated fraction (Fig. 3A) was identical to that of authentic Ap 7 A (labeled in Fig. 3E ). To answer the question how the phosphoesters are connected to the riboses of the adenosines, the products generated by nucleotide hydrolase digestion and alkaline phosphatase were analyzed. Incubation of the isolated molecules with alkaline phosphatase (Fig. 3B) or 3Ј-nucleotide hydrolase (calf spleen) (Fig. 3C) yielded no cleavage products. When Ap 7 A recovered from biological extracts was treated with 5Ј-nucleotide hydrolase (Crotalus durissus), the initial peak of Ap 7 A decreased, and the hydrolysis products AMP and adenosine hexaphosphate appeared (Fig. 3D) . The cleavage pattern was identical with that of authentic Ap 7 A (Fig. 3E) . The results of the enzymatic cleavage experiments demonstrate that the polyphosphate chain interconnects the two adenosines via phosphoester bonds to the 5Ј-positions of the riboses.
After platelet aggregation with thrombin, Ap 7 A is released into the extracellular space. Fig. 4 shows the anion exchange chromatogram before (Fig. 4A) and after platelet aggregation with thrombin (Fig. 4B) . Ap 7 A can be found in the supernatant after platelet aggregation (labeled in Fig. 4B by an arrow) . The extracellular concentration of Ap 7 A can be estimated by the UV peak in the range of 0.05-0.1 mol/liter after thrombin stimulation. The concentration of Ap 7 A in the supernatant of untreated platelet extract was lower than the detection limit (detection limit was Ͻ5 nmol/liter; Fig. 4) .
Furthermore, the amounts of diadenosine polyphosphates released were determined in relation to the total amounts. The portion released upon platelet aggregation was estimated as 60% for each diadenosine polyphosphate.
At basal tone, Ap 7 A caused a dose-dependent vasoconstriction (Fig. 5A) . The vasoconstrictor EC 50 value (mol/liter) of (Fig. 5A) . The minimal effective concentration of Ap 7 A was less than 10 Ϫ5 mol/ liter. Ap 7 A is less effective on the vascular resistance of the isolated perfused rat kidney than ␣,␤-methylene ATP, Ap 5 A, or Ap 6 A.
In the presence of suramin (100 mol/liter) and PPADS (30 mol/liter), the responses of kidney vasculature to Ap 6 A and Ap 7 A were completely abolished. The response of Ap 7 A in the presence and absence of PPADS and suramin is shown in Fig.  5 , B and C, respectively. Incubation of the isolated perfused rat kidney with ␣,␤-methylene ATP abolished the vasoconstrictive effect of Ap 7 A (Fig. 6 ). Since no vasodilator response to Ap 7 A was seen, even after vascular tone was increased by ␣,␤-methylene ATP, no further antagonists specific for P2Y receptors were tested. Conversely, the vasoconstrictive effect of angiotensin II was not affected under continuous perfusion with ␣,␤-methylene ATP.
Ap 7 A has no direct effect on aggregation of isolated platelets (data not shown). However, the ADP-induced platelet aggregation is inhibited by Ap 7 A. The concentration dependence of Ap 7 A on the inhibition of ADP-induced platelet aggregation is shown in Fig. 7 . The IC 50 value of Ap 7 A on the inhibitory effect of ADP aggregation was calculated at (2.94 Ϯ 0.88) ϫ 10 Ϫ6 mol/liter; the value for Ap 6 A was (2.68 Ϯ 0.74) ϫ 10 Ϫ6 mol/liter; and the value for Ap 5 A was (4.06 Ϯ 0.92) ϫ 10 Ϫ6 mol/liter.
DISCUSSION
In the last decade, diadenosine polyphosphates Ap n A (n ϭ 3-6) received considerable attention in view of their multiple biological and pharmacological activities. Besides their role in platelet aggregation (16) , diadenosine polyphosphates have potent vasoconstrictive and vasodilator properties. The vasoactive actions of diadenosine polyphosphates were demonstrated in numerous vascular models (17) .
Comparison of the various diadenosine polyphosphates reveals that the action of these compounds on vasculature depends on the number of phosphate groups. Accordingly, vasodilation can be observed in intact vessels after administration of Ap 2 A, Ap 3 A, and Ap 4 A, whereas Ap 5 A and Ap 6 A are vasoconstrictive (17) . Our results demonstrate for the first time a diadenosine polyphosphate with a vasoconstrictive effect with seven phosphate groups. The vasoconstrictive effect of Ap 7 A is comparable with the effect of Ap 5 A, the diadenosine polyphosphate with the most intensive vasoconstrictive effect known (7) .
To the best of our knowledge, unlike diadenosine polyphos- phates Ap n A with n ϭ 3-6, Ap 7 A has not been isolated from any tissue so far. The question arises of how this substance is biosynthesized. In general, four classes of enzymes are known to synthesize dinucleoside polyphosphates in vitro (for a review, see Ref. 18): Ap 4 A phosphorylases, luciferases, guanylyl transferases, and the aminoacyl-tRNA synthetases. However, these enzymes are not capable of producing of dinucleoside polyphosphates in vivo. In vivo Ap 4 A is enzymatically synthesized from ATP and lysine by lysyl-sRNA synthetase. This pathway was shown using baby hamster kidney cells, salmonella, and Escherichia coli (18) . Principally, this pathway is also capable of producing Ap 7 A.
Alternatively, a nonenzymatic synthesis may be considered. Given that mostly mononucleotides such as ATP are found together with biogenic amines such as catecholamines, the coexistence of both nucleotides and amines within the same subcellular localization may be due to the type of nonenzymatic reaction generating diadenosine polyphosphates. From ATP and a biogenic amine, a phosphoramidate may be generated, which is a highly reactive intermediate. A further reaction with another ATP could then yield Ap 6 A. However, also diadenosine polyphosphates with a higher length of the phosphate chain could be produced by this reaction, if an additional step to add phosphates to the phosphoramidate is assumed.
The experiment with the P 2 purinoceptor antagonist, suramin, and the P 2x purinoceptor antagonist, PPADS, suggests that the vasoconstrictive action of Ap 7 A is due to activation of P 2x purinoceptors. During perfusion with maximally effective concentrations of ␣,␤-methylene ATP, Ap 7 A did not further increase vascular resistance. These experiments further support the view that Ap 7 A produces vasoconstriction via P 2x purinoceptors. Because P 2x1 receptors have been identified in rat kidney (19) and ␣,␤-methylene ATP is a specific agonist for the P 2x1 subtype (20) , the vasoconstrictive effect of Ap 7 A is probably mediated by the P 2x1 subtype.
Principally, Ap 7 A appears to act by the same mechanisms as Ap 5 A and Ap 6 A (14). The latter diadenosine polyphosphates were shown to exert vasoconstriction via the P 2x purinoceptor, whereas Ap 2 A and Ap 3 A are vasodilators, acting via A 2 receptors (5). Chan et al. (19) further characterized the P 2x receptor in rat kidney vasculature as the P 2x subtype. Present results strongly suggest that Ap 7 A also activates this P 2x purinoceptor subtype. Compared with Ap 5 A and Ap 6 A, its receptor affinity as estimated from the EC 50 value appears to be less, suggesting that the optimal length of the phosphate chain to activate the P 2x purinoceptor may be five phosphates.
Because of the different vascular effects of diadenosine polyphosphates, depending on the number of phosphate groups, it may be speculated that for both adenosine moieties in the molecules an optimal distance exists to have a vasoconstrictive effect. The EC 50 value of Ap 5 A and Ap 6 A indicates a slightly higher receptor affinity of Ap 5 A and Ap 6 A than of Ap 7 A, suggesting that the optimal distance between the adenosine moieties of the known endogenous diadenosine polyphosphates is achieved with five phosphate groups.
After the biochemical characterization, the question arose of whether the concentration range of Ap 7 A used in the isolated perfused rat kidney is physiologically relevant. Compared with ATP, which can easily be identified in chromatograms of platelet extracts, the concentration of Ap 7 A may be in the range of 1 ⁄200 to 1 ⁄500 ATP. Earlier experiments showed that about 80% of diadenosine polyphosphates of platelets are released during aggregation (21) . Obviously, the diadenosine polyphosphate concentration occurring in extracellular space after platelet aggregation depends on the volume of distribution, but the intraplatelet concentrations suggest that in the close environment of platelet thrombus similar diadenosine polyphosphate concentrations can be found as in platelets. In particular, platelets and chromaffin granules of the adrenal medulla have rather high concentrations of diadenosine polyphosphates (Ap n A; n ϭ 3-6), which was up to 6 mmol/liter. Local extracellular concentration of up to 100 mol/liter have been assumed (22) .
The physiological role of Ap 7 A is still unclear. Like Ap n A (n ϭ 3-6), (3, 4, 8) , Ap 7 A is released by platelet aggregation.
Furthermore, Ap 7 A may thereby reach extracellular concentrations sufficient to affect vasculature, as estimated from the concentration-response curves in the isolated perfused rat kidney. The experiments revealed a lower EC 50 of Ap 7 A compared with Ap 5 A and Ap 6 A. Obviously, in the sigmoidal part of the concentration-response curve, Ap 7 A has weaker effects than Ap 5 A and Ap 6 A. However, this does not necessarily imply that the extracellular effects of Ap 7 A are negligible; e.g. due to the long phosphate chain, the affinity of hydrolases may be lower and hence the extracellular half-life may be longer than that of the other diadenosine polyphosphates. Therefore, Ap 7 A may be involved in local changes of perfusion induced by platelet aggregation.
Ap 7 A inhibits ADP-induced platelet activation which is mediated via the P2Y1 and P2T AC receptor (23). Inhibition of platelet aggregation by diadenosine polyphosphates was proposed to be due to competition between the dinucleotides and ADP at a specific receptor site on the platelet membrane (24) , which, according to experiments with a recombinant P2Y1 receptor, is not identical with the latter (25) . Therefore the inhibitory action may be developed at the P2T AC receptor. Ap 5 A has the highest inhibitory activity on platelet aggregation, followed by Ap 6 A and Ap 7 A. This is in good agreement with the results of Harrison et al. (24) .
Like the other diadenosine polyphosphates, Ap 7 A may not only occur in platelets, but also in adrenal medulla and sympathetic nerve endings, although no attempts have been made to isolate Ap 7 A from cells other than platelets. Assuming the same widespread occurrence of Ap 7 A as of the other analogues, a role as sympathetic co-transmitter may be discussed. However, the physiological concentrations of Ap 7 A appear to be lower than those of Ap 5 A and Ap 6 A, at least in human platelets. At present, potential differences in the effects of Ap 5 A, Ap 6 A, and Ap 7 A have not been studied yet.
In summary, Ap 7 A isolated from human platelets appears to be a potent vasoconstrictor whose vasoconstrictive effect is mediated by a P 2x receptor, possibly by the P 2x1 subtype of this receptor. Furthermore Ap 7 A inhibits platelet aggregation.
